Essilor : Disclosure of Share Capital and Voting Rights Outstanding as of
June 30, 2014
(Pursuant to Article L.233-8 II of the French Commercial Code and articles
221-1 and 223-16 of the General Regulations of the Autorité des Marchés
CHARENTON-LE-PONT, France -- July 3, 2014
Regulatory News :
As of June 30, 2014, shares and voting rights outstanding of Essilor
(Paris:EI), the world leader in ophthalmic optics, broke down as follows:
June 30, 2014
Shares outstanding 215,096,782
Exercisable voting rights 226,637,870
Total voting rights, based on all outstanding shares, 231,300,811
including shares stripped of their voting rights*
(*) Shares held by the Company.
The world’s leading ophthalmic optics company, Essilor designs, manufactures
and markets a wide range of lenses to improve and protect eyesight. Its
corporate mission is to improve lives by improving sight. To support this
mission, the Company allocates more than €150 million to research and
innovation every year, in a commitment to continuously bring new, more
effective products to market. Essilor’s flagship brands are Varilux®, Crizal®,
Transitions®, Definity®, Xperio®, OptifogTM, Foster Grant®, Bolon® and Costa®.
It also develops and markets equipment, instruments and services for eyecare
Essilor reported consolidated revenue of over €5 billion in 2013 and employs
more than 55,000 people. It distributes its products in some 100 countries
with 28 plants, more than 450 prescription laboratories and edging facilities,
as well as several research and development centers around the world.
For more information, please visit www.essilor.com.
The Essilor share trades on the NYSE Euronext Paris market and is included in
the Euro Stoxx 50 and CAC 40 indices.
Codes and symbols: ISIN: FR0000121667; Reuters: ESSI.PA; Bloomberg: EI:FP.
Investor Relations and Financial Communication
Véronique Gillet – Sébastien Leroy – Ariel Bauer, Tel.: +33 (0)1 49 77 42 16
Press spacebar to pause and continue. Press esc to stop.